This quarterly report arrives at an unusual moment for CBZ. In July 2026, the professional services firm agreed to be acquired by Grant Thornton, backed by New Mountain Capital, in an all-cash deal valued at $5.0 billion, or $55.00 per share. Because the transaction is pending, CBZ did not issue full-year 2026 guidance or host a conference call. As a result, investors are weighing the strength of underlying operations against a deal that is expected to take the company private. The results offer a final independent look at demand across the firm's Financial Services and Benefits and Insurance Services segments before the acquisition is expected to close later in the year. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For the third quarter ended September 30, 2026, CBZ reported total revenue of $702.2 million, a 1.2% increase from $693.8 million in the prior-year period but below analysts' consensus estimate of about $727.7 million. Financial Services revenue grew 1.2% to $597.8 million, while Benefits and Insurance Services revenue rose 1.0% to $104.4 million.
Net income increased 56.7% to $47.2 million, and GAAP diluted EPS rose to $0.79 from $0.48 a year ago. Adjusted diluted EPS of $1.21 fell short of the $1.28 consensus expectation. Adjusted EBITDA climbed 6.3% to $131.9 million, with an adjusted EBITDA margin of 18.8%, up from 17.9% in the year-ago quarter.
For the nine months ended September 30, 2026, total revenue rose 0.8% to $2.23 billion, while net income increased 12.2% to $219 million. Adjusted diluted EPS grew 5.9% to $4.64. Operating cash flow improved by $98 million and free cash flow by $91 million compared with the prior-year period.
CBZ shares were little changed in after-hours trading following the release, reflecting how the pending acquisition has largely anchored the stock near the $55.00-per-share deal price. With the stock trading in the mid-$54 range, sentiment is dominated less by quarterly fundamentals than by progress toward closing the transaction. The EPS and revenue shortfalls against consensus are notable, but they carry limited weight for a stock whose near-term value is tied to an agreed cash offer. Investor attention has instead shifted to the deal's approval process, including shareholder consent and regulatory clearances, which remain the primary drivers of the share price heading into the fourth quarter.
The most important catalyst ahead is the completion of the Grant Thornton acquisition. The transaction is expected to close in the fourth quarter of 2026, subject to shareholder approval, regulatory clearances, and other customary closing conditions. Once completed, CBZ's common stock will no longer be listed on the New York Stock Exchange, and the company will become private.
Until then, investors will be watching for any updates on the regulatory review process, the shareholder vote, and whether any closing conditions are waived or delayed. Any sign that the deal could be renegotiated, terminated, or pushed beyond its expected timeline would likely matter far more to the stock than a single quarter's results.
From an operating standpoint, the third quarter showed modest revenue growth but improved profitability, with expanding gross margin and adjusted EBITDA margin. Demand across both the Financial Services and Benefits and Insurance Services segments remained steady but subdued. However, with guidance suspended and no earnings call scheduled, there is limited additional operating detail for investors to assess until the transaction resolves.
In my own research process, Tickeron's AI Screener has become a go-to resource for quickly filtering stocks by fundamentals, technical patterns, and sector trends. It allows me to compare earnings performance across peers and spot potential opportunities without spending hours on manual data pulls. This kind of tool helps keep the focus on what matters most when evaluating situations like the one with CBZ.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CBZ's Aroon Indicator triggered a bullish signal on November 09, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 268 similar instances where the Aroon Indicator showed a similar pattern. In 183 of the 268 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 68%.
Following a +0.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBZ advanced for three days, in 219 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The 10-day RSI Indicator for CBZ moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 17 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 49%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 75 cases where CBZ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
CBZ broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. CBZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.617) is normal, around the industry mean (5.887). P/E Ratio (26.306) is within average values for comparable stocks, (33.618). Projected Growth (PEG Ratio) (1.219) is also within normal values, averaging (1.946). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (1.214) is also within normal values, averaging (9.907).
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CBZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of financial and employee benefits services
Industry OfficeEquipmentSupplies